Conference Support

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology

Medical Writer: Stijn van den Borne, MSc
Updated: 11 September 2017

YOU MAY ALSO LIKE

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology.

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology (CSA), held from 7-10 September 2017 in Zhengzhou, Henan Province, PR China.

We would like to extend our gratitude to the inviting partner, the CSA, and doctors for making time to meet our medical writer.

The Annual Meeting of the CSA, the official anaesthetist chapter of the Chinese Medical Association, is the largest anaesthesiology meeting in China.

1 2 3 4 5 6 7 8 9

© Copyright 2017 - MediPaper - 25th Annual Meeting of the Chinese Society of Anaesthesiology - CSA2017 - 中华医学会第25 次全国麻醉学术年会

You may also like

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 23-Apr-2018

First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

NCT02578680 Keynote189 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Nonsquamous NSCLC

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

I-O in Special Populations: Diabetes and Concomitant Steroids

Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

Nivolumab for NPC: immunotherapy active in nasophareyngeal carcinoma (NCI-9742)

Making sense of immunotherapy in NSCLC

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

Symposium Highlight 5HT3 NK1 Palonosetron Netupitant CINV Chemotherapy-induced Nausea and Vomiting

Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2017 - MediPaper - CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology